CSTL Gears Up to Report Q4 Earnings: Here's What You Should Know

Core Viewpoint - Castle Biosciences, Inc. is set to report its fourth-quarter and full-year 2024 results on February 27, with revenue expectations of $85.7 million and earnings of 11 cents per share [1][10]. Group 1: Company Performance - In the past year, shares of Castle Biosciences have increased by 5.1$320-330 million [5]. Group 2: Revenue Drivers - The company's revenues for the upcoming quarter are likely to be driven by higher sales from its innovative test solutions for dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions [4]. - Activities related to research, development, and commercialization of new tests may have increased operating expenses in the quarter [6]. Group 3: Earnings Surprise History - Castle Biosciences has a strong history of earnings surprises, having beaten earnings estimates in each of the last four quarters with an average surprise of 172.72% [9]. - In the last reported quarter, the company achieved an earnings surprise of 233.33% [9]. Group 4: Earnings Expectations - The Earnings ESP for Castle Biosciences is 0.00%, as both the Most Accurate Estimate and the Zacks Consensus Estimate are at 11 cents [11]. - The company currently holds a Zacks Rank of 2 (Buy) [11].